Maintenance therapy after first‐line therapy for ovarian cancer: Quantitative effectiveness

Documenti analoghi

• Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
  di: Lingying Wu, et al.
  Pubblicazione: (2025)
• The association between menopausal hormone therapy and breast cancer remains unsettled
  di: Mike Fillon
  Pubblicazione: (2024)
• Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
  di: Akshara Singareeka Raghavendra, et al.
  Pubblicazione: (2026)
• Erectile dysfunction common within the first year after rectal cancer surgery
  di: Mike Fillon
  Pubblicazione: (2025)
• The evolving landscape of tissue‐agnostic therapies in precision oncology
  di: Vivek Subbiah, et al.
  Pubblicazione: (2024)